MENLO PARK, Calif.–(BUSINESS WIRE)–
Pacific Biosciences of California, Inc. (NASDAQ: PACB), provider of
Single Molecule Real Time (SMRT®) sequencing products,
announced today that the company has partnered with Cycle Computing to
optimize the PacBio RS SMRT Analysis software for the cloud.
Preliminary demonstrations of the solution will be presented this week
by Cycle Computing at the Bio-IT World Cloud Computing conference on
September 20 in La Jolla, California and the Amazon Web Services
Genomics Event on September 22 in Seattle, Washington.
The cloud-based version of the SMRT Analysis software suite is designed
to provide dynamic, high performance computing that scales to meet the
data analysis needs for SMRT sequencing and supports a workflow that
includes sample preparation, sequencing and completed data analysis in
less than one day. A beta version of the solution is expected to be
available with the next major PacBio RS upgrade, currently
scheduled for the end of 2011.
“Analysis of long, single molecule, real-time sequencing reads from
unamplified samples without the need to maintain complex and expensive
hardware and software will offer customers more flexibility to realize
the potential of the PacBio RS,” said Edwin Hauw, Director of
Software Product Management for Pacific Biosciences. “By leveraging
Cycle Computing’s expertise in building scalable, high performance cloud
computing applications our goal is to provide the best balance of
performance and convenience for customers.”
For more information about PacBio’s SMRT Analysis software, see the
PacBio DevNet site at https://www.pacbiodevnet.com.
For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.
You can also follow the company on Twitter: www.twitter.com/pacbio.
About Pacific Biosciences
Pacific Biosciences’ mission is to transform the way humankind acquires,
processes and interprets data from living systems through the design,
development and commercialization of innovative tools for biological
research. The company has developed a novel approach to studying the
synthesis and regulation of DNA, RNA and proteins. Combining recent
advances in nanofabrication, biochemistry, molecular biology, surface
chemistry and optics, Pacific Biosciences has created a powerful
technology platform called single molecule, real-time, or SMRT®,
technology. SMRT technology enables real-time analysis of biomolecules
with single molecule resolution, which has the potential to transform
the understanding of biological systems by providing a window into these
systems that has not previously been open for scientific study.
This press release contains forward-looking statements. Forward-looking
statements may contain words such as “believe,” “may,” “estimate,”
“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of
these terms, or other similar expressions, and include the assumptions
that underlie such statements. Such statements include, but are not
limited to, statements regarding the Company’s SMRT technology. These
statements are subject to known and unknown risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements, including but not limited to risks discussed
from time to time in documents Pacific Biosciences of California, Inc.
has filed with the Securities and Exchange Commission, including the
risks identified under the section captioned “Risk Factors” in its
recently filed Quarterly Report on Form 10-Q. All forward-looking
statements are based on estimates, projections and assumptions as of the
date hereof. Pacific Biosciences undertakes no obligation to update any
For Pacific Biosciences
Nicole Litchfield, 415-793-6468 (Media)
Trevin Rard, 650-521-8450 (Investors)
Articulate Communications Inc.
212-255-0080, ext. 11 (Media)
Source: Pacific Biosciences of California, Inc.
News Provided by Acquire Media